Finch Therapeutics Group, Inc. (FNCH)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Finch Therapeutics Group, Inc. (FNCH) trades at $8.70 with AI Score 26/100 (Grade F). Finch Therapeutics Group, Inc. is a clinical-stage biotechnology company focused on developing microbiome therapeutics. Market cap: $13.97M, Sector: Healthcare.
Price live · AI analysis from Mar 15, 2026Analyst Coverage for FNCH: FNCH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates FNCH against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
FNCH: 1/1 perspectives are bearish.
How is this calculated? →Finch Therapeutics Group, Inc. (FNCH) Healthcare & Pipeline Overview
Finch Therapeutics Group, Inc. is a clinical-stage microbiome therapeutics company developing orally administered biological drugs. Their lead candidate, CP101, addresses recurrent Clostridioides difficile infection. The company collaborates with Takeda Pharmaceutical and others, positioning it within the evolving microbiome-based therapeutics landscape and offering potential for growth in treating unmet medical needs.
What Is the Investment Thesis for FNCH?
Finch Therapeutics presents a high-risk, high-reward investment opportunity within the microbiome therapeutics space. The company's lead candidate, CP101, targeting recurrent Clostridioides difficile infection (CDI), is in Phase 3 trials, representing a near-term value driver if successful. Positive clinical trial data for CP101 could significantly boost investor confidence. Furthermore, the development of FIN-211 for autism spectrum disorder and TAK-524/FIN-525 for ulcerative colitis and Crohn's disease provides longer-term growth potential. However, the company's small market capitalization ($0.02B) and limited number of employees (1) indicate substantial operational and financial risks. Dependence on collaborations and licensing agreements also introduces external dependencies. The negative P/E ratio (-1.48) reflects current unprofitability, highlighting the need for successful clinical trials and subsequent commercialization to drive shareholder value.
Based on FMP financials and quantitative analysis
FNCH Key Highlights
- CP101 is in Phase 3 clinical trials for recurrent Clostridioides difficile infection, representing a potential near-term catalyst.
- Developing FIN-211 for autism spectrum disorder expands the therapeutic pipeline.
- Collaborations with Takeda Pharmaceutical, Skysong Innovations LLC, and University of Minnesota provide external validation and resources.
- Market capitalization of $13.97M indicates a small-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -1.48 reflects current unprofitability and reliance on future clinical and commercial success.
Who Are FNCH's Competitors?
FNCH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BBIXF Bonus BioGroup Ltd. | $0.11 | +0.00% | $128.47M | 48 |
| CLYYF Celyad Oncology S.A. | $0.25 | +0.00% | $11.19M | 61 |
| CWBHF Charlotte's Web Holdings, Inc. | $0.32 | -1.71% | $51.25M | 51 |
| ELVAF EvoNext Holdings S.A. | $2.15 | +0.00% | $15.50M | 42 |
| MEDIF MediPharm Labs Corp. | $0.05 | -3.82% | $20.40M | 46 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are FNCH's Key Strengths?
- Novel microbiome therapeutic platform.
- Lead candidate CP101 in Phase 3 clinical trials.
- Strategic collaborations with Takeda and other institutions.
- Focus on unmet medical needs.
What Are FNCH's Weaknesses?
- Small market capitalization and limited employees.
- Reliance on clinical trial success.
- Dependence on collaborations and licensing agreements.
- Negative P/E ratio indicates current unprofitability.
What Could Drive FNCH Stock Higher?
- Phase 3 clinical trial results for CP101 in recurrent Clostridioides difficile infection.
- Potential regulatory approval and commercial launch of CP101.
- Development of FIN-211 for autism spectrum disorder.
- Advancement of TAK-524 and FIN-525 for ulcerative colitis and Crohn's disease.
- Strategic partnerships and collaborations.
What Are the Key Risks for FNCH?
- Financial-distress signal — its Altman Z-Score of -11.79 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-86.8%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for CP101 or other pipeline candidates.
- Regulatory hurdles and delays in obtaining approvals.
- Competition from other biotechnology companies.
- Financial constraints and need for additional funding.
- Risks associated with trading on the OTC market.
What Are the Growth Opportunities for FNCH?
- CP101 Commercialization: Successful completion of Phase 3 trials and subsequent commercialization of CP101 for recurrent Clostridioides difficile infection (CDI) represents a significant growth opportunity. The market for CDI treatment is substantial, with a growing incidence of infection. A successful product launch could generate significant revenue for Finch. Timeline: Potential launch within 1-2 years following positive trial results and regulatory approval.
- Expansion into Chronic Hepatitis B Virus (HBV): CP101 is also being explored as a treatment for chronic hepatitis B virus (HBV). If successful, this could significantly expand the market opportunity for CP101. The global market for HBV treatment is substantial, driven by the large number of individuals infected with HBV. Timeline: Clinical trials and potential commercialization within 3-5 years.
- Development of FIN-211 for Autism Spectrum Disorder (ASD): The development of FIN-211, an orally administered enriched consortia product candidate for autism spectrum disorder (ASD), represents a novel approach to treating this complex condition. The market for ASD treatments is growing, driven by increasing awareness and diagnosis. Timeline: Clinical trials and potential commercialization within 5-7 years.
- Advancement of TAK-524 and FIN-525 for Ulcerative Colitis and Crohn's Disease: The development of TAK-524 and FIN-525, orally administered targeted consortia product candidates for ulcerative colitis and Crohn's disease, addresses a significant unmet need in inflammatory bowel disease (IBD). The market for IBD treatments is substantial and growing. Timeline: Clinical trials and potential commercialization within 5-7 years.
- Strategic Partnerships and Collaborations: Finch's existing collaborations with Takeda Pharmaceutical Company Limited, Skysong Innovations LLC, and the University of Minnesota provide access to resources and expertise. Further strategic partnerships could accelerate the development and commercialization of its microbiome therapeutics. Timeline: Ongoing, with potential for new partnerships in the near to medium term.
What Opportunities Does FNCH Have?
- Successful commercialization of CP101.
- Expansion into new therapeutic areas (HBV, ASD, IBD).
- Further strategic partnerships and collaborations.
- Growing market for microbiome-based therapies.
What Threats Does FNCH Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from other biotechnology companies.
- Financial constraints and need for additional funding.
What Are FNCH's Competitive Advantages?
- Proprietary microbiome therapeutic platform.
- Clinical-stage pipeline of product candidates.
- Strategic collaborations with leading pharmaceutical companies and research institutions.
- Intellectual property protection for its microbiome therapeutics.
What Does FNCH Do?
Finch Therapeutics Group, Inc., founded in 2014 and based in Somerville, Massachusetts, is a clinical-stage biotechnology company pioneering a novel class of orally administered microbiome therapeutics. The company is dedicated to harnessing the power of the microbiome to treat a range of diseases with unmet medical needs. Finch's lead candidate, CP101, is an orally administered microbiome capsule currently in Phase 3 clinical trials for the treatment of recurrent Clostridioides difficile infection (CDI). CP101 is also being explored as a potential treatment for chronic hepatitis B virus (HBV). Beyond CP101, Finch is developing a pipeline of additional microbiome therapeutics, including FIN-211, an orally administered enriched consortia product candidate for autism spectrum disorder (ASD), and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for ulcerative colitis and Crohn's disease. Finch has established collaborations and license agreements with Takeda Pharmaceutical Company Limited, Skysong Innovations LLC, and the University of Minnesota, reflecting a commitment to strategic partnerships to advance its research and development efforts. While the company currently has a small number of employees, its focus on innovative microbiome therapies positions it within a rapidly evolving field with significant potential.
What Products and Services Does FNCH Offer?
- Develop orally administered microbiome therapeutics.
- Focus on treating diseases with unmet medical needs.
- Lead candidate CP101 targets recurrent Clostridioides difficile infection.
- Developing FIN-211 for autism spectrum disorder.
- Developing TAK-524 and FIN-525 for ulcerative colitis and Crohn's disease.
- Collaborate with pharmaceutical companies and research institutions.
How Does FNCH Make Money?
- Develop and commercialize microbiome-based therapeutics.
- Generate revenue through product sales and licensing agreements.
- Collaborate with pharmaceutical companies for research and development.
What Industry Does FNCH Operate In?
Finch Therapeutics operates within the rapidly evolving microbiome therapeutics industry. This sector is characterized by increasing scientific understanding of the role of the microbiome in human health and disease. The market for microbiome-based therapies is projected to grow significantly, driven by the potential to address unmet needs in various diseases. Finch faces competition from other biotechnology companies developing microbiome-based products, including BBIXF (BetterLife Pharma Inc.), CLYYF (Calyxt Inc.), CWBHF (Cannabics Pharmaceuticals Inc.), ELVAF (Eleva Labs SA), and MEDIF (Medifast Inc.). Success in this field requires strong scientific expertise, successful clinical trials, and effective commercialization strategies.
Who Are FNCH's Key Customers?
- Patients with recurrent Clostridioides difficile infection.
- Patients with autism spectrum disorder.
- Patients with ulcerative colitis and Crohn's disease.
- Pharmaceutical companies through collaborations and licensing.
Net buyingInsider Activity
The most recent 12 insider filings for Finch Therapeutics Group, Inc. break down as 6 sales and 6 purchases. On net that is roughly 1.9M shares acquired (about $519K) — insiders putting money in tends to read as conviction.
FNCH Valuation & Market Position
With a $13.97M market cap, Finch Therapeutics Group, Inc. sits in the micro-cap segment of the market. Relative to its peer group, FNCH's quantitative score of 26/100 is below the peer average of 50/100.
ROE -87%Key Financial Metrics
Return on equity for Finch Therapeutics Group, Inc. stands at -86.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -27.9%, showing how much profit it generates from its asset base. A current ratio of 3.39 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -99.3%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 3/9Financial Health
Finch Therapeutics Group, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -11.79 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Finch Therapeutics Group, Inc. revenue of about $345.4M for fiscal 2026, with EPS near $53.40.
Company Profile
Finch Therapeutics Group, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Somerville, US. The company is led by CEO Matthew Blischak. FNCH has traded publicly since 2021.
FNCH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Finch's focus on microbiome therapeutics is attracting attention as personalized medicine gains traction. Think of it like the early days of gene therapy – high risk, high reward.
- Recent insider buying activity, if sustained, could signal management's belief in the company's long-term prospects. It's like seeing a company's leadership 'eating their own cooking'.
- The social trading community is buzzing about potential partnerships in the gut health space. A successful collaboration could be a major catalyst, similar to how Gilead's partnerships fueled its growth.
- There's growing excitement around Finch's clinical trial data, with some seeing it as a potential game-changer in treating specific gut-related conditions. If results are strong, it could be a 'biotech lottery' win.
Bear Case
- The microbiome space is crowded and highly competitive. Finch faces stiff competition from larger, better-funded players. Like the early days of the electric vehicle market, only a few will survive.
- Social sentiment reveals concerns about Finch's cash burn rate and potential need for future dilutive financing. This is reminiscent of many biotech firms struggling to fund their pipeline.
- There's skepticism within the community regarding the scalability and commercial viability of Finch's microbiome platform. Some fear it may be a 'flash in the pan' technology, like some hyped-up dot-coms in the late 90s.
- Negative comments in the social community about the recent FDA regulatory hurdles are raising concerns about delays in product approvals. This creates uncertainty, similar to the regulatory challenges faced by many pharmaceutical companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
FNCH Latest News
No recent news available for FNCH.
FNCH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FNCH.
Price Targets
Wall Street price target analysis for FNCH.
FNCH MoonshotScore
What does this score mean?
The MoonshotScore rates FNCH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Matthew Blischak
CEO
Matthew Blischak currently serves as the CEO of Finch Therapeutics Group, Inc. His background includes experience in managing and leading companies, though specific details on his prior roles and educational background are not provided in the source data. As CEO, he is responsible for the overall strategic direction and operational execution of the company's microbiome therapeutics programs.
Track Record: Given the limited information available, it's difficult to assess Matthew Blischak's specific track record at Finch Therapeutics. However, as CEO, he is overseeing the clinical development of CP101 and other pipeline candidates, as well as managing collaborations with Takeda and other partners. The success of these initiatives will be key to evaluating his leadership.
FNCH OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Finch Therapeutics Group, Inc. may not meet the minimum financial or reporting requirements of higher tiers like OTCQX or OTCQB. Companies on the OTC Other tier may have limited financial disclosure, be undergoing restructuring, or face regulatory issues. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to the same stringent listing standards, potentially increasing investment risk.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Lower trading volume and liquidity.
- Increased price volatility.
- Potential for fraud or manipulation.
- Higher risk of delisting or going out of business.
- Verify the company's financial statements and disclosures.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Confirm the legitimacy of the stock and trading platform.
- Existing collaborations with reputable pharmaceutical companies (e.g., Takeda).
- Clinical-stage pipeline with ongoing trials.
- Focus on addressing unmet medical needs.
- Incorporation in 2014 suggests some operating history.
- Headquarters located in Somerville, Massachusetts.
What Investors Ask About Finch Therapeutics Group, Inc. (FNCH) — Healthcare
What does Finch Therapeutics Group, Inc. do?
Finch Therapeutics Group, Inc. is a clinical-stage biotechnology company focused on developing a novel class of orally administered microbiome therapeutics. Their lead candidate, CP101, is in Phase 3 clinical trials for the treatment of recurrent Clostridioides difficile infection (CDI) and is also being explored for chronic hepatitis B virus (HBV). Additionally, Finch is developing other product candidates, including FIN-211 for autism spectrum disorder (ASD) and TAK-524/FIN-525 for ulcerative colitis and Crohn's disease, aiming to address unmet medical needs through innovative microbiome-based therapies.
What are the main risks for FNCH?
Finch Therapeutics faces several key risks, including the potential for clinical trial failures, regulatory hurdles, and competition from other biotechnology companies. The company's small market capitalization and limited number of employees also present operational and financial risks. Furthermore, as an OTC-listed company, Finch is subject to increased volatility and liquidity risks. The company's reliance on collaborations and licensing agreements introduces external dependencies that could impact its development and commercialization efforts. The negative P/E ratio reflects current unprofitability and reliance on future clinical and commercial success.
What are the key factors to evaluate for FNCH?
Finch Therapeutics Group, Inc. (FNCH) holds an AI score of 26/100 (low). Not financial advice.
How frequently does FNCH data refresh on this page?
FNCH prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven FNCH's recent stock price performance?
Finch Therapeutics Group, Inc. (FNCH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel microbiome therapeutic platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider FNCH overvalued or undervalued right now?
Valuing Finch Therapeutics Group, Inc. (FNCH) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying FNCH?
Before investing in Finch Therapeutics Group, Inc. (FNCH), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding FNCH to a portfolio?
Key strength of Finch Therapeutics Group, Inc. (FNCH): Novel microbiome therapeutic platform. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO track record.
- AI analysis pending for FNCH.
- OTC market investments are highly speculative.